1 / 25

Shedding Light on HDL: Myths and Controversies

Shedding Light on HDL: Myths and Controversies. The HDL Hypothesis. Residual Clinical Risk in Statin Trials. TNT: On-Treatment HDL-C Predicts CV Event 5-Year Risk When LDL-C is <70 mg/dL. Infusing HDL Slows Development and Promotes Regression of Atherosclerosis. AIM-HIGH: Study Design.

hidi
Download Presentation

Shedding Light on HDL: Myths and Controversies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Shedding Light on HDL: Myths and Controversies

  2. The HDL Hypothesis

  3. Residual Clinical Risk in Statin Trials

  4. TNT: On-Treatment HDL-C Predicts CV Event 5-Year Risk When LDL-C is <70 mg/dL

  5. Infusing HDL Slows Development and Promotes Regression of Atherosclerosis

  6. AIM-HIGH: Study Design

  7. AIM-HIGH: HDL-C After 36 Months of Follow-up

  8. Current Pharmacologic Approaches to Raising HDL-C

  9. SATURN: Change in LDL-C and HDL-C From Baseline

  10. Evidence From Prior Placebo-controlled Trials Supporting Niacin Benefit

  11. CETP Inhibitors: Past and Present

  12. CETP Deficiency

  13. CETP Deficiency: Genotype

  14. ILLUMINATE: Protocol-Specified Outcomes

  15. DEFINE: Blood Pressure Results at 18 Months

  16. Evacetrapib: BP Results

  17. Comparison of CETP Inhibitors

  18. DEFINE: Effect of Anacetrapib on Lp(a)

  19. Ongoing CETP Outcomes Trials

  20. Abbreviations

  21. Abbreviations (cont)

More Related